文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

新型血管加压药驱动的感染性休克死亡预测模型的开发与性能

Development and performance of a novel vasopressor-driven mortality prediction model in septic shock.
PubMed 文献 · Ann Intensive Care · 2018-11-22
一句话结论在感染性休克患者中,纳入定量血管加压药使用的MAVIC模型对28天和1年死亡率的预测优于APACHE-III和SOFA评分。

该研究在5352例感染性休克患者中计算定量血管加压药使用量,比较去甲肾上腺素当量(NEE)、累积血管加压药指数和血管活性肌力评分模型,选择区分度最好的log10NEE,通过向后逐步logistic回归开发MAVIC模型(机械通气、急性生理与慢性健康评估III、血管加压药、正性肌力药、Charlson合并症指数)。在独立验证队列中,MAVIC预测28天死亡率(AUROC 0.73 vs. 0.66和0.60)和1年死亡率(AUROC 0.74 vs. 0.66和0.60)均优于APACHE-III和SOFA评分。

要点

  • 在5352例感染性休克患者中,log10NEE因区分度最佳被选入MAVIC模型开发。
  • MAVIC模型预测28天死亡率AUROC 0.73,优于APACHE-III的0.66和SOFA的0.60。
  • MAVIC模型预测1年死亡率AUROC 0.74,优于APACHE-III的0.66和SOFA的0.60。
  • MAVIC模型包含机械通气、APACHE-III、血管加压药、正性肌力药和Charlson合并症指数。

适用人群与场景

  • 感染性休克患者(开发队列5352例,验证队列为独立人群)。

研究设计与关键结果

  • 研究类型为预测模型开发与验证研究;开发队列5352例感染性休克患者,比较NEE、累积血管加压药指数和血管活性肌力评分模型,log10NEE区分度最佳。
  • 通过向后逐步logistic回归开发MAVIC模型(机械通气、APACHE-III、血管加压药、正性肌力药、Charlson合并症指数)。
  • 在独立验证队列中,MAVIC预测28天死亡率AUROC 0.73,优于APACHE-III的0.66和SOFA的0.60。
  • MAVIC预测1年死亡率AUROC 0.74,优于APACHE-III的0.66和SOFA的0.60。

证据类型、等级与局限

  • 证据类型:预测模型开发与验证研究;原文未报告证据等级。
  • 局限:原文未报告局限性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Vasoactive medications are essential in septic shock, but are not fully incorporated into current mortality prediction risk scores. We sought to develop a novel mortality prediction model for septic shock incorporating quantitative vasoactive medication usage.

METHODS: Quantitative vasopressor use was calculated in a cohort of 5352 septic shock patients and compared using norepinephrine equivalents (NEE), cumulative vasopressor index and the vasoactive inotrope score models. Having best discrimination prediction, log10NEE was selected for further development of a novel prediction model for 28-day and 1-year mortality via backward stepwise logistic regression. This model termed 'MAVIC' (Mechanical ventilation, Acute Physiology And Chronic Health Evaluation-III, Vasopressors, Inotropes, Charlson comorbidity index) was then compared to Acute Physiology And Chronic Health Evaluation-III (APACHE-III) and Sequential Organ Failure Assessment (SOFA) scores in an independent validation cohort for its accuracy in predicting 28-day and 1-year mortality.

MEASUREMENTS AND MAIN RESULTS: The MAVIC model was superior to the APACHE-III and SOFA scores in its ability to predict 28-day mortality (area under receiver operating characteristic curve [AUROC] 0.73 vs. 0.66 and 0.60) and 1-year mortality (AUROC 0.74 vs. 0.66 and 0.60), respectively.

CONCLUSIONS: The incorporation of quantitative vasopressor usage into a novel 'MAVIC' model results in superior 28-day and 1-year mortality risk prediction in a large cohort of patients with septic shock.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Vallabhajosyula S, Jentzer JC, Kotecha AA, et al. Development and performance of a novel vasopressor-driven mortality prediction model in septic shock. Ann Intensive Care. 2018. PMID: 30467807. doi:10.1186/s13613-018-0459-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。